SCHEMBL17599323

SCHEMBL17599323

O=C(O)c1cccc(-c2ccc(NS(=O)(=O)c3c(Cl)nc4sccn34)c3ccccc23)c1

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ACLY P53396 2/20 0.63
CCKBR P32239 1/20 0.46
HTR6 P50406 15/20 0.44
KMT2A Q03164 1/20 0.41
ADRB2 P07550 1/20 0.41
CHRM2 P08172 1/20 0.41
ADRA2A P08913 1/20 0.41
S1PR1 P21453 1/20 0.41
C5AR1 P21730 1/20 0.41
SLC6A2 P23975 1/20 0.41
FPR3 P25089 1/20 0.41
HTR1D P28221 1/20 0.41
HTR1B P28222 1/20 0.41
HTR2A P28223 1/20 0.41
HTR2C P28335 1/20 0.41
GPR183 P32249 1/20 0.41
HTR7 P34969 1/20 0.41
ADRA1A P35348 1/20 0.41
HRH1 P35367 1/20 0.41
ADRA1B P35368 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21999792 0.78 ACLY (1.00) ACLYCCKBR
SCHEMBL17599382 0.75 WDR5 (0.45) ACLYKMT2A
SCHEMBL17599353 0.74 ACLY (0.58) ACLYKMT2A
SCHEMBL17599406 0.73 ACLY (0.58) ACLYKMT2A
SCHEMBL17599407 0.73 ACLY (0.58) ACLYKMT2A
SCHEMBL17599379 0.73 ACLY (0.54) ACLYKMT2A
SCHEMBL17599340 0.72 SLC16A3 (0.58) ACLYKMT2A
SCHEMBL17599360 0.72 ITGA1 (0.56) ACLYKMT2ABCL2L1
SCHEMBL17599343 0.72 KEAP1 (0.46) ACLYKMT2A
SCHEMBL17599327 0.72 ACLY (0.61) ACLYKMT2ABCL2BCL2L1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2998294-A1 Naphthyl sulfonamide phenyl derivatives as KEAP-1 modulators for the treatment of diabetes, obesity, dyslipidemia and related disorders SANOFI (FR) 2016-03-23 EP disclosed
EP-2998294-A1 Naphthyl sulfonamide phenyl derivatives as KEAP-1 modulators for the treatment of diabetes, obesity, dyslipidemia and related disorders SANOFI (FR) 2016-03-23 EP disclosed